Paediatric ocular adnexal lymphoma: a population-based analysis

Giannis A Moustafa, Allan K Topham, Mary E Aronow, Demetrios G Vavvas

ABSTRACT

Objective To investigate the incidence, clinicopathological characteristics and survival of ocular adnexal lymphoma (OAL) in the paediatric population.

Methods and analysis In this retrospective case series, the Surveillance, Epidemiology and End Results database was accessed to identify individuals with OAL ≤18 years of age, diagnosed between 1973 and 2015. OAL located in the eyelid, conjunctiva, lacrimal apparatus and orbit were included. Main outcome measures were the age-adjusted incidence rates (IRs) per 1 000 000 population at risk (calculated for the period 2000–2015) and descriptive statistics of demographic and clinicopathological features.

Results The IR of paediatric OAL was 0.12 (95% CI 0.08 to 0.16) per 1 000 000. Males (0.15; 95% CI 0.10 to 0.22) and blacks (0.24; 95% CI 0.13 to 0.42) had a higher tendency for OAL development. A total of 55 tumours in 54 children were identified. The majority were localised (78.4%), conjunctival (49.1%) lymphomas. Extranodal marginal zone lymphoma (EMZL, 45.5%, n=25) was the most frequent subtype, followed by diffuse large B-cell lymphoma (DLBCL, 9.1%, n=5), B lymphoblastic lymphoma (7.3%, n=4), follicular lymphoma (5.5%, n=3), Burkitt lymphoma (5.5%, n=3), anaplastic large cell lymphoma (ALCL, 3.6%, n=2), small lymphocytic lymphoma (1.8%, n=1), diffuse large B-cell lymphoma, immunoblastic (1.8%, n=1) and panniculitis-like T-cell lymphoma (1.8%, n=1). Localised, low-grade, conjunctival lymphomas were frequently treated with complete excision with or without radiation, while high-grade and distant tumours usually received chemotherapy. Only 29.1% of paediatric OAL cases were treated with radiation. Three out of five (60%) patients with DLBCL died of lymphoma at a median follow-up of 21 (range 10–86) months, and 1 out of 2 (50%) patients with ALCL died of lymphoma at 23 months from diagnosis.

Conclusion OAL in the paediatric population is rare. The majority of OAL are EMZL and are characterised by excellent prognosis. The histological subtype was found to be the main predictor of outcome with cancer-specific deaths observed in patients with DLBCL and ALCL.

INTRODUCTION

Non-Hodgkin’s lymphoma (NHL) comprises a diverse spectrum of lymphoproliferative diseases and represents 4%–5% of new cancer cases each year. Primary NHL of the ocular region represents 1%–2% of all NHL and 5%–15% of all extranodal sites. It can be intraocular (vitreoretinal or uveal lymphoma), but most commonly develops in the ocular adnexal structures, including the eyelid, conjunctiva, lacrimal apparatus, and orbit.

Ocular adnexal lymphoma (OAL) predominantly affects the elderly, with a reported annual incidence rate of 2 per 100 000 in persons above 70 years of age. Most commonly, it is a low-grade lymphoproliferation, characterised by a prolonged, indolent course. Presenting symptoms can include proptosis, periorbital oedema, conjunctival ‘salmon patch’, visual changes and rarely pain from increased intraocular pressure. In children and adolescents, OAL is exceedingly rare and incidence is unknown.

Current understanding of OAL epidemiology and outcomes in the paediatric population is predominantly based on case reports and data from series pertaining to the adult lymphoma literature. We hypothesise...
that significant differences exist between paediatric and adult OAL that have not yet been described. This study aims to investigate the incidence, as well as clinical, histological and survival characteristics of paediatric patients with OAL using data from a national population-based cancer registry. Similar to recent multicentre studies on OAL, a subtype-focused analysis was performed, in order to highlight clinical and survival features that are subtype-specific.5–7

**MATERIALS AND METHODS**

**Data source**
The cohort of patients was abstracted from the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) database, incorporating data derived from 18 cancer registries and covering approximately 28% of the total US population based on the 2010 US census.20 The SEER 18 registries include: San Francisco, San Jose-Monterey, Los Angeles, the Greater California area, Atlanta (Metropolitan), rural Georgia, the Greater Georgia area, Connecticut, Detroit/Michigan, Hawaii, Iowa, New Mexico, Seattle-Puget Sound/Washington, Utah, Alaska, Kentucky, Louisiana and New Jersey.

**Coding and study cohorts**
The following inclusion criteria were applied: (i) tumour classified as NHL according to the International Classification of Diseases for Oncology, third edition (ICD-O-3), using morphology codes: 9590–9596, 9670–9726, 9728–9729, 9811–9837,27 (ii) tumour located in the eyelid, conjunctiva, lacrimal apparatus and orbit using ICD-O-3 topographic codes: C44.1, C69.0-C69.1, C69.3, C69.5-C69.827 and (iii) patient age ≤18 years. Exclusion criteria were: (i) tumour not histologically or cytologically confirmed and (ii) cases diagnosed from autopsy or death certificates.

**Data extraction**
Demographic, clinicopathological features and survival data were extracted using the SEER ‘case listing’ module. Tumour stage was recoded based on the SEER summary stage for OAL as follows: (1) localised, defined as lymphoma limited to ocular adnexa; (2) regional, defined as lymphoma extending to adjacent structures such as bone and brain and/or regional node (preauricular, submandibular, cervical) involvement and (3) distant, defined as non-contiguous involvement of other extranodal sites (parotid gland, submandibular gland, lung, liver, spleen, kidney, breast, etc) and/or diffuse or disseminated involvement of peripheral and central lymph node regions.28 The American Joint Committee on Cancer (AJCC) Collaborative Stage and AJCC tumour-node-metastasis (TNM) stage, seventh edition, were also reported for tumours diagnosed in 2004 or later and 2010 or later, respectively.20 30 Data regarding treatment selection (surgery, radiation and chemotherapy) were also obtained. Surgery was documented as complete excision, debulking procedure or enucleation.

**Statistical analysis**
For population analysis, incidence rates were determined in a two-step process using the SEER*Stat software. First, age-specific rates were calculated using census estimates for the population and the 42-year period of time studied (therefore adjusting for population increases). Consequently, age-specific rates were standardised to the age distribution of the US population as reported in the 2000 US census and expressed as per 1 000 000 population at risk. This step corrected for changes and variations in age distribution over time. We calculated IRs from 2000 to 2015 for two reasons: first, we aimed to include the largest cohort of patients, since only 9 registries had been included for the period 1973–2015, while all 18 SEER registries had been added after 2000; second we wanted to account for the misdiagnosis of OAL as reactive lymphoid hyperplasia prior to the routine utilisation of immunohistochemical techniques.31

In the cohort analysis, Stata V.15 (StataCorp) and Prism V.8 (GraphPad Software) were used for descriptive and survival statistics. Non-specified histology (9590/3: malignant lymphoma, NOS and 9591/3: non-Hodgkin’s lymphoma, NOS) were listed as unknown. Categorical variables are presented as absolute number and percentages, and continuous outcomes as median and range. Kaplan–Meier curves were used to determine survival over time. Univariate survival analysis was executed using the log-rank test. For pairwise comparisons of multiple groups, post hoc analysis with Bonferroni correction was applied. The α level of significance was set at 0.05 and p values were two-sided.

**RESULTS**

**Population analysis**
The age-adjusted incidence of primary paediatric OAL was 0.12 (95% CI 0.08 to 0.16) per 1 000 000 children aged 0–18 years (table 1). Paediatric males and blacks demonstrated a higher tendency for OAL development, although the results were not statistically significant: males 0.15 (95% CI 0.10 to 0.22), females 0.08 (95% CI 0.04 to 0.13), blacks 0.24 (95% CI 0.13 to 0.42), whites 0.10 (95% CI 0.06 to 0.14), Hispanics 0.10 (95% CI 0.05 to 0.18) and Asians 0.03 (95% CI 0.00 to 0.17).

**Ocular adnexal lymphoma cohort analysis**
Fifty-five primary OAL tumours in 54 children were identified. One patient was diagnosed with two primary ocular lymphomas (different histology), one of which was bilateral. No other preceding or subsequent malignancies were observed in our cohort. The median age at diagnosis was 13 (range 1–18) years and the median follow-up duration was 81 (range 0–418) months. A total of 36 (66.7%) patients were male. Twenty-five (46.3%) patients were white, 15 (27.8%) were black, 11 (20.4%) were Hispanic and 2 (3.7%) were Asian. Six (10.9%) tumours were bilateral. Overall, the conjunctiva was the most common primary site (conjunctiva 49.1%,...
Moustafa GA, et al. BMJ Open Ophth 2020;5:e000483. doi:10.1136/bmjophth-2020-000483

complete excision alone, 7 (35.0%) with excision and radiation, 1 (5.0%) with radiation only and 1 (5.0%) with chemotherapy only (table 3). Two patients with localised orbital tumours were treated with complete excision and excision plus radiation, respectively. Surgery combined with radiation was also used for a patient with conjunctival primary OAL and distant disease, while a patient with orbital EMZL and metastases was treated with chemotherapy. The median follow-up was 70 months (range, 7–213), and during this time, no deaths were observed.

**Diffuse large B-cell lymphoma**

Five (9.1%) patients were diagnosed with DLBCL. The median age was 15 years (range 2–17). Three patients (60.0%) were male, four (80.0%) were white and one (20.0%) was black. Three cases (60.0%) originated in the orbit, one (20.0%) in the conjunctiva and one (20.0%) in the lacrimal gland, and all tumours were unilateral. Stage was localised for two patients (66.7%) and distant for one patient (33.3%). All patients received chemotherapy regardless of tumour location, except for the patient with the lacrimal tumour, for whom treatment was documented as none/unknown (table 3). Three patients (60.0%) died of lymphoma at 10, 21 and 86 months from diagnosis, and two (40.0%) were alive at their last visit 92 and 154 months from diagnosis.

**Lymphoblastic B-cell lymphoma**

Four (7.3%) patients were diagnosed with precursor B-cell lymphoblastic lymphoma, one of whom displayed Philadelphia translocation. The median age was 5 (3–7) years. All patients were white females and were diagnosed with unilateral orbital tumours. Two of the three patients with Philadelphia-negative B-LBL had localised disease. One of them received chemotherapy and the other chemotherapy plus ‘debulking’ surgery (table 3). The third patient with Philadelphia-negative B-LBL was diagnosed with metastatic disease and was treated with chemotherapy. The patient with Philadelphia-positive B-LBL had distant disease at diagnosis and was treated with chemotherapy. All patients were alive at a median follow-up of 91.5 (range 46–178) months.

**Follicular lymphoma**

Three (5.5%) patients were diagnosed with FL. The median age at diagnosis was 13 (range 10–15) and all patients were male. One patient (33.3%) was white and two (66.7%) patients were black. A patient with bilateral, localised conjunctival FL was treated with surgery alone (table 3). Since this patient was diagnosed in 2015, no follow-up visits are documented. A patient with distant eyelid lymphoma was treated with chemotherapy. The third patient was diagnosed with a localised, left lacrimal gland FL and a localised, bilateral, conjunctival EMZL. No cancer-directed surgery or radiation was performed for the FL, but it is unknown if the patient received chemotherapy. Both patients with orbit 38.2%, lacrimal gland 9.1%, eyelid 3.6%), and the majority of cases were diagnosed at an early SEER stage (72.7% were localised).

The following mature B-cell lymphoma subtypes were identified: 25 (45.5%) extranodal marginal zone lymphoma (EMZL) cases, 5 (9.1%) diffuse large B-cell lymphoma (DLBCL) cases, 3 (5.5%) follicular lymphoma (FL) cases, 3 (5.5%) Burkitt lymphoma (BL) cases, 1 (1.8%) small lymphocytic lymphoma case and 1 (1.8%) diffuse large B-cell lymphoma, immunoblastic (DLBCLI) case. The following mature T-cell lymphoma subtypes were identified: 2 (3.6%) anaplastic large T/null-cell lymphoma (ALCL) cases, and 1 (1.8%) panniculitis-like T-cell lymphoma case. Finally, 4 (7.3%) B-cell lymphoblastic lymphomas were identified, one of which was Philadelphia translocation-positive. Of the 10 OALs with unknown histological subtype, one was of B-cell origin and one of NK-cell origin, but no further classification could be made. Table 2 summarises the clinicopathological characteristics of paediatric OAL by histological subtype.

**B-cell lymphoma subtypes**

**Extranodal marginal zone lymphoma**

Twenty-five (45.5%) patients were diagnosed with EMZL. The median age was 15 years (range 5–18), and 20 (80.0%) were male. Eight (33.3%) patients were white, 9 (37.5%) black, 6 (25.0%) Hispanic and 1 (4.2%) Asian. Twenty-two (88.0%) were located in the conjunctiva and 22 (91.7%) were localised at diagnosis. Five tumours (20.8%) were bilateral. Of the 20 patients with localised conjunctival tumours, 9 (45.0%) were treated with complete excision alone, 7 (35.0%) with excision and radiation, 1 (5.0%) with radiation only and 1 (5.0%) with chemotherapy only (table 3). Two patients with localised orbital tumours were treated with complete excision and excision plus radiation, respectively. Surgery combined with radiation was also used for a patient with conjunctival primary OAL and distant disease, while a patient with orbital EMZL and metastases was treated with chemotherapy. The median follow-up was 70 months (range, 7–213), and during this time, no deaths were observed.

**Table 1** Incidence rates (IRs) of paediatric ocular adnexal lymphoma in the US population for the period 2000–2015

| Race          | Paediatric OAL cases, no. | Age-adjusted IR* (95% CI) |
|---------------|--------------------------|--------------------------|
| White         | 16                       | 0.10 (0.06 to 0.14)      |
| Black         | 13                       | 0.24 (0.13 to 0.42)      |
| Hispanic      | 10                       | 0.10 (0.05 to 0.18)      |
| Asian         | 1                        | 0.03 (0.00† to 0.17)     |
| Other/Unknown | 2                        | N/A                      |

*IRs were expressed per 1000000 person-years.
†IR or 95% CI limit <0.005.
N/A, not available.

Overall 42 0.12 (0.08 to 0.16)
Age at diagnosis, years
1–6 6 0.05 (0.02 to 0.10)
7–12 13 0.12 (0.06 to 0.20)
13–18 23 0.20 (0.13 to 0.30)
Gender
Male 28 0.15 (0.10 to 0.22)
Female 14 0.08 (0.04 to 0.13)
Race
White 16 0.10 (0.06 to 0.14)
Black 13 0.24 (0.13 to 0.42)
Hispanic 10 0.10 (0.05 to 0.18)
Asian 1 0.03 (0.00† to 0.17)
Other/Unknown 2 N/A

...
| No. (%)*                  | B-cell lymphoma | T-cell lymphoma | Unknown | Total |
|--------------------------|-----------------|-----------------|---------|-------|
|                           | EMZL | DLBCL | B-LBL | FL  | BL  | SLL  | DLBCLI | ALCL | PTCL |       |       |
| Total                    | 25 (46)| 5 (9) | 4 (7) | 3 (5) | 3 (5) | 1 (2) | 1 (2) | 2 (4) | 1 (2) | 10 (18) | 55 |
| Age at diagnosis, years† | 15 (5–18) | 15 (2–17) | 5 (3–7) | 13 (10–15) | 11 (1–11) | 17 | 8 | 16 (15–17) | 9 | 13 (2–18) | 13 (1–18) |
| Gender†                  |       |       |       |       |       |       |       |       |       |       |       |
| Male                     | 20 (80)| 3 (60)| 0     | 3     | 1    | 0    | 1 (50) | 0    | 6 (60) | 36 (67) |       |
| Female                   | 5 (20)| 2 (40)| 4     | 0     | 0    | 0    | 1 (50) | 1    | 4 (40) | 18 (33) |       |
| Race†                    |       |       |       |       |       |       |       |       |       |       |       |
| White                    | 8/24 (33)| 4 (80)| 4     | 1 (33)| 2 (67)| 1    | 1    | 2     | 1     | 5 (60) | 25 (46) |
| Black                    | 9/24 (38)| 1 (20)| 0     | 2 (67)| 0    | 0    | 0    | 0     | 0     | 3 (60) | 15 (28) |
| Hispanic                 | 6/24 (25)| 0     | 0     | 1 (33)| 0    | 0    | 0    | 0     | 0     | 1 (10) | 11 (20) |
| Asian                    | 1/24 (4) | 0     | 0     | 0     | 0    | 0    | 0    | 0     | 0     | 1 (10) | 2 (4) |
| Site                     |       |       |       |       |       |       |       |       |       |       |       |
| Conjunctiva              | 22 (88)| 1 (20)| 0     | 1 (33)| 0    | 0    | 0    | 0     | 0     | 3 (60) | 27 (49) |
| Orbit                    | 3 (12)| 3 (60)| 4     | 0     | 2 (67)| 1    | 1    | 2     | 1     | 4 (40) | 21 (38) |
| Lacrimal                 | 0     | 1 (20)| 0     | 1 (33)| 1 (33)| 0    | 0    | 0     | 0     | 2 (20) | 5 (9) |
| Eyelid                   | 0     | 0     | 0     | 1 (33)| 0    | 0    | 0    | 0     | 0     | 1 (10) | 2 (4) |
| Summary stage            |       |       |       |       |       |       |       |       |       |       |       |
| Localised                | 22/24 (92)| 2/3 (67)| 2 (50)| 2 (67)| 1 (1) | 1    | 1    | 1     | 0     | 8/9 (89) | 40/51 (78) |
| Regional                 | 0     | 0     | 0     | 0     | 0    | 0    | 0    | 1 (50)| 0    | 1/9 (11) | 2/51 (4) |
| Distant                  | 2/24 (8)| 1/3 (33)| 2 (50)| 1 (33)| 2 (67)| 0    | 0    | 1 (50)| 0    | 0     | 9/51 (18) |
| AJCC Collaborative Stage |       |       |       |       |       |       |       |       |       |       |       |
| IE                       | 16/17 (94)| 1/1 | 1/3 (33)| 2 (67)| 0    | 0    | 0    | 0     | 1     | 3     | 23/28 (82) |
| IIE                      | 0     | 0     | 0     | 0     | 0    | 0    | 0    | 0     | 0     | 0     | 0 |
| IIIE                     | 0     | 0     | 0     | 1 (33)| 0    | 0    | 0    | 1     | 0    | 0     | 2/28 (7) |
| IVE                      | 1/17 (6)| 0 | 2/3 (67)| 0    | 0    | 0    | 0    | 0     | 0     | 0     | 3/28 (11) |
| AJCC TNM stage           |       |       |       |       |       |       |       |       |       |       |       |
| T1                       | 11 (85)| 0 | 0     | 1     | 0    | 0    | 0    | 0     | 0     | 0     | 0 | 12/17 (71) |
| T2                       | 1 (8) | 0 | 0     | 0     | 0    | 0    | 0    | 0     | 0     | 1     | 2/17 (12) |
| T3                       | 0     | 0 | 0     | 0     | 0    | 0    | 0    | 0     | 0     | 1     | 0 | 1/17 (6) |
| T4                       | 1 (8) | 0 | 0     | 1     | 0    | 0    | 0    | 0     | 0     | 0     | 0 | 2/17 (12) |
| Laterality               |       |       |       |       |       |       |       |       |       |       |       |
| OD                       | 12/24 (50)| 4 (80)| 1 (25)| 0 | 1 (33)| 1 | 0 | 1 (50)| 1 | 5 (50) | 26/54 (48) |

Continued
| Year of diagnosis | B-cell lymphoma | T-cell lymphoma | Unknown | Total |
|-------------------|-----------------|-----------------|---------|-------|
|                   | EMZL | DLBCL | B-LBL | FL | BL | SLL | DLBCLI | ALCL | PTCL |         |       |
| OS                | 7/24 (29) | 1 (20) | 3 (75) | 2 (67) | 2 (67) | 0 | 1 | 1 (50) | 0 | 5 (50) | 22/54 (41) |
| OU                | 5/24 (21) | 0 | 0 | 1 (33) | 0 | 0 | 0 | 0 | 0 | 0 | 6/54 (11) |
| 1973–1988         | 0 | 1 (20) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 (20) | 3 (6) |
| 1989–2001         | 5 (20) | 1 (20) | 1 (25) | 0 | 1 (33) | 0 | 1 | 1 (50) | 0 | 5 (50) | 12 (22) |
| 2002–2015         | 20 (80) | 3 (60) | 3 (75) | 3 | 2 (67) | 0 | 0 | 1 (50) | 1 | 3 (30) | 40 (73) |
| Vital status at last follow-up | | | | | | | | | | | |
| Alive             | 25 | 2 (40) | 4 | 3 | 3 | 0 | 1 | 0 | 1 | 10 | 49 (91) |
| Dead of lymphoma  | 0 | 3 (60) | 0 | 0 | 0 | 0 | 0 | 1 (50) | 0 | 0 | 4 (7) |
| Dead of other causes | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 (50) | 0 | 0 | 2 (4) |

*Percentages were rounded up to integer numbers and may not add up to 100%.
†For estimating the total number in patient-specific variables, the patient diagnosed with both primary EMZL and primary FL was counted once.
AJCC, American Joint Committee on Cancer; AKL, positive; ALCL, anaplastic large T/null-cell lymphoma; BK, Burkitt lymphoma; B-LBL, lymphoblastic B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; DLBCLI, diffuse large B-cell lymphoma, immunoblastic; EMZL, extranodal marginal zone lymphoma; FL, follicular lymphoma; OD, right eye; OS, left eye; OU, both eye; PTCL, panniculitis-like T-cell lymphoma; SLL, small lymphocytic lymphoma; TNM, tumour-node-metastasis.
Table 3  Management of paediatric ocular adnexal lymphoma by tumour location, histological subtype and stage

| No. (%)* | Total* | S only | R only | C only | S+R | S+C | R+C | S+R+C | No treatment/Unknown |
|----------|--------|--------|--------|--------|-----|-----|-----|-------|---------------------|
| **Conjunctival tumours** |        |        |        |        |     |     |     |       |                     |
| DLBCL/Localised | 1 (2) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| FL/Localised | 1 (2) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EMZL/Localised | 20 (36) | 9 (45) | 1 (5) | 1 (5) | 7 (35) | 0 | 0 | 0 | 2 (10) |
| EMZL/Distant | 1 (2) | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| EMZL/Unknown | 1 (2) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown/Localised | 2 (4) | 0 | 1 (50) | 0 | 0 | 1 (50) | 0 | 0 | 0 |
| Unknown/Unknown | 1 (2) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Orbital tumours** |        |        |        |        |     |     |     |       |                     |
| SLL/Localised | 1 (2) | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| DLBCL/Localised | 1 (2) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| DLBCL/Distant | 1 (2) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| DLBCL/Unknown | 1 (2) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| DLBCL/Localised | 1 (2) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| BL/Distant | 2 (4) | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| EMZL/Localised | 2 (4) | 1 (50) | 0 | 0 | 1 (50) | 0 | 0 | 0 | 0 |
| EMZL/Distant | 1 (2) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| PTCL/Localised | 1 (2) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| ALC/Regional | 1 (2) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| ALC/Distant | 1 (2) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| B-LBL/Localised | 2 (4) | 0 | 0 | 1 (50) | 0 | 1 (50) | 0 | 0 | 0 |
| B-LBL/Distant | 1 (2) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Ph/Distant | 1 (2) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Unknown/Localised | 3 (5) | 1 (33) | 0 | 0 | 1 (33) | 0 | 1 (33) | 0 | 0 |
| Unknown/Regional | 1 (2) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| **Lacrimal tumours** |        |        |        |        |     |     |     |       |                     |
| DLBCL/Unknown | 1 (2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| BL/Localised | 1 (2) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| FL/Localised | 1 (2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown/Localised | 2 (4) | 1 (50) | 0 | 1 (50) | 0 | 0 | 0 | 0 | 0 |
| **Eyelid tumours** |        |        |        |        |     |     |     |       |                     |
| FL/Distant | 1 (2) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Unknown/Localised | 1 (2) | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| **Total** | 55 | 15 (27) | 3 (5) | 12 (22) | 9 (16) | 8 (15) | 1 (2) | 3 (5) | 4 (7) |

*Percentages were rounded up to integer numbers and may not add up to 100%.

ALCL, anaplastic large T/null-cell lymphoma; BL, Burkitt lymphoma; B-LBL, lymphoblastic B-cell lymphoma; C, chemotherapy; DLBCL, diffuse large B-cell lymphoma; DLBCLI, diffuse large B-cell lymphoma, immunoblastic; EMZL, extranodal marginal zone lymphoma; FL, follicular lymphoma; Ph, lymphoma with Philadelphia translocation; PTCL, panniculitis-like T-cell lymphoma; R, radiation; S, surgery; SLL, small lymphocytic lymphoma.

documented follow-up were alive 80 and 130 months from diagnosis.

**Burkitt lymphoma**

Three (5.5%) patients were diagnosed with BL. The median age was 11 (range 1–11) and all patients were male. Two (66.7%) were whites and one (33.3%) was of Hispanic origin. Two patients with unilateral orbital BLs and metastases were treated with chemotherapy (table 3). A patient with unilateral, localised, lacrimal gland BL was treated with tumour excision plus chemotherapy. All patients were alive at 195, 156 and 157 month follow-up from diagnosis, respectively.

**Small lymphocytic lymphoma**

A boy aged 17 years was diagnosed with localised SLL of the right orbit, which was treated with radiation (table 3). Sixty-nine months after diagnosis he died of ‘accidents and adverse effects’.

---

Moustafa GA, et al. BMJ Open Ophth 2020;5:e000483. doi:10.1136/bmjophth-2020-000483
Figure 1  OS and CS of children with ocular adnexal lymphoma (A) as a whole, and stratified by (B) tumour histological subtype, (C) tumour location and (D) tumour stage. CS, cancer-specific; OS, overall survival; ALCL, anaplastic large T/null-cell lymphoma; B-LBL, lymphoblastic B-cell lymphoma; BL, Burkitt lymphoma; DLBCL, diffuse large B-cell lymphoma; DLBCLI, diffuse large B-cell lymphoma, immunoblastic;EMZL, extranodal marginal zone lymphoma; FL, follicular lymphoma; Ph, lymphoma with Philadelphia translocation; PTCL, panniculitis-like T-cell lymphoma; SLL, small lymphocytic lymphoma.

**Diffuse large B-cell lymphoma, immunoblastic**
A girl aged 8 years was diagnosed with localised DLBCLI of the left orbit, and received a combination of surgery, radiation and chemotherapy (table 3). She was alive 311 months after diagnosis.

**T-cell lymphoma subtypes**

**Anaplastic large T/null-cell lymphoma**
A white boy aged 17 years was diagnosed with regional ALCL, anaplastic lymphoma kinase-positive (ALK+) of the right orbit. An excisional biopsy was performed accompanied by radiation and chemotherapy (table 3). The patient died of lymphoma 23 months after diagnosis. A white girl aged 15 years was diagnosed with distant ALCL, ALK+ of the left orbit. The patient was treated with enucleation and chemotherapy but died 3 months after diagnosis due to ‘cerebrovascular diseases’.

**Panniculitis-like T-cell lymphoma**
A white girl aged 9 years was diagnosed with localised PTCL of the right orbit. The patient underwent complete excision and chemotherapy (table 3) and was alive 32 months from diagnosis.

**Survival analysis**
For the whole paediatric cohort, the 5-year overall (OS) and cancer-specific (CS) survival was 92.1% (95% CI 80.3% to 97.0%) and 93.9% (95% CI 82.2% to 98.0%), respectively (figure 1A). Final OS and CS was 86.1% (95% CI 71.1% to 93.7%) and 90.4% (95% CI 75.6% to 96.4%), respectively (figure 1A). Six (11.1%) children died at a median follow-up of 22 (range 3–86) months. Three children with DLBCL died of lymphoma at a median follow-up of 21 (range 10–86) months and a patient with ALCL, ALK+ died of lymphoma at 23 months from diagnosis. DLBCL histology (Bonferroni-corrected p<0.001 OS and CS, log-rank test; figure 1B), ALCL histology (Bonferroni-corrected p<0.001 for OS and CS, log-rank test; figure 1B), orbital involvement (p=0.02 for OS and p=0.07 for CS, log-rank test; figure 1C) and advanced stage (p=0.06 for OS and p=0.05 for CS, log-rank test; figure 1D) were significantly associated with higher mortality.

**DISCUSSION**
This study represents a population-based description of primary OAL in the paediatric population in the USA, using data available from the SEER registry. The histological spectrum was broad with EMZL accounting for nearly half of paediatric OAL cases.4–7 32–35 While still rare, the percentages of BL and T-cell lymphomas were higher compared with adult OAL cohorts, whereas FL was less commonly observed.5–7 36 None of the T-cell lymphomas originated on the eyelids, which is the highest-risk area for T-cell OAL development.6

While lymphoblastic lymphoma generally develops from immature T-cells, lymphoblastic OAL in children
was of B-cell origin in all specified cases. Our findings are in line with the large cohorts in the literature showing that B-LBL of the ocular adnexa is primarily a disease of children and young adults. In a study by Jenkins et al, all four lymphoblastic lymphomas in a cohort of 192 patients with ocular adnexal lymphoma were diagnosed in children, three of which demonstrated a B-cell phenotype. Similarly, in a multicentre study by Olsen et al, three out of four B-LBLs in a cohort of 797 patients with orbital lymphoma were diagnosed in children aged 12 years or less. In a study by Sjö et al, two out of three B-LBLs in a cohort of 228 ophthalmic lymphomas were seen in children, while in a cohort of 353 OALs, the one lymphoblastic lymphoma diagnosed in a child was a precursor B lymphoblastic lymphoma.

The conjunctiva was by far the most common location of paediatric EMZL, as opposed to adults, where the orbit is the most frequently involved anatomical structure. It is possible that orbital tumours may have been underdiagnosed in the paediatric age group, due to the less frequent use of neuro-imaging techniques in children, which require anaesthesia. However, aggressive histological subtypes, such as DLBCL, BL, T-cell lymphomas and B-LBLs, demonstrated a predilection for the orbit. While the conjunctiva was most frequently affected, it is important to note that most conjunctival lesions in children are benign. In a large series reporting on conjunctival tumours observed in 262 children, only 3% were malignant and only 1.5% represented a lymphoid proliferation.

In contrast to adult OAL, which is characterised by equal gender distribution or a slight female predominance, males in the paediatric population demonstrated higher risk for OAL development. Moreover, while in the USA the risk of OAL is higher in the white population, black children in our study exhibited a higher tendency towards OAL development.

Radiotherapy, the most commonly used therapy for localised adult OAL, was less frequently used in the paediatric population, possibly owing to its side effects, which can be detrimental in children—namely cataract formation, dry eye, keratitis, retinopathy, facial bony deformities and the life-long risk of secondary malignancies. Similar to adult OAL, chemotherapy was the preferred treatment for advanced stages and more aggressive histological subtypes in our cohort (table 3 and figure 2). Excision of the tumour alone was performed mainly in the case of localised, low-grade, unilateral tumours, particularly of the conjunctiva (table 3 and figure 2), in accordance with case reports and other reports on paediatric ocular adnexal lymphoma and lymphoma in general. During the follow-up period that lasted for up to 35 years from diagnosis, no second primary malignancies were observed in our cohort. More focused multicentre studies are needed to establish these patients’ risk for second malignancy development and association with radiation therapy and chemotherapy.

Overall and subtype-specific survival rates were comparable to survival in adults. The histological subtype was the primary predictor of outcome, with DLBCL and ALCL demonstrating higher mortality. Orbital involvement and advanced stage seem to also contribute to prognosis; however, this may be explained by the fact that these high-grade lymphomas were frequently located in the orbit and were commonly advanced at diagnosis. Similar to the 90%–96% disease-specific survival of ocular adnexal marginal zone lymphoma, no deaths were witnessed among patients with EMZL in our cohort. Similarly, no deaths were also documented among the patients with FL.

The rarity of OAL in children and adolescents hampers the feasibility of large-scale investigations. Our data were derived from a large, population-based cancer registry that spans over four decades. To our knowledge, this is the first study investigating this rare entity. Our findings can be a reference point for clinicians who encounter these cases.

Limitations of our study include its retrospective design and missing data on chemotherapy and use of rituximab, radiation dose, immunodeficiency, patient symptomatology, tumour recurrences, immunohistochemistry and the presence of multifocal disease. Moreover, due to the rarity of paediatric OAL, the sample size may not be adequate for subgroup analyses and for achieving statistical significance in IR differences. Finally, in this study, staging categorisation was largely based on the SEER summary stage, rather than the TNM-based staging which is frequently used in clinical practice.

![Figure 2](image.png)  
**Figure 2** Treatment of paediatric ocular adnexal lymphoma according to (A) tumour stage, (B) tumour location and (C) tumour grade.
In summary, our study provides insight on the clinicopathological features and survival of paediatric OAL per histological subtype. EMZL comprised the majority of tumours. Radiotherapy may be less frequently used in children. Future studies should supplement our data with the radiation doses and chemotherapy regimens used in this patient group.

Acknowledgements The authors would like to thank Gerasimos Tsilimidos, MD (Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland) for his insight and for reviewing the manuscript.

Contributors GAM conceptualised the study, searched the literature, analysed the data, wrote and revised the manuscript; AKT provided statistical feedback and revised the manuscript; MEA revised the manuscript; DGV conceptualised the study, revised the manuscript, earned funding for the study and supervised the whole work.

Funding This study was supported by the Yeatts Family Foundation (DGV); Monte J. Wallace (DGv); 2013 Macula Society Research Grant Award (DGV); a Physician Scientist Foundation (DGV); unrestricted grant from the Research to Prevent Blindness Foundation (DGV); National Eye Institute (NEI) R21EY023079-01/A1 (DGv); Loeffler Family Fund (DGV); RO1EY25362-01 (DGv); ARI Young Investigator Award (DGV); Foundation Lions Eye Research Fund (DGv).

Competing interests DGV is consultant to Olix Therapeutics and Valitor and co-founder of The Therapeutics.

Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

Patient consent for publication Not required.

Ethics approval This study was approved by the Massachusetts Eye and Ear Institutional Review Board & Partners Human Research (Protocol #: 2019P001227). Our study and data accumulation were in conformity with all country, federal or state laws, and the study adhered to the tenets of the Declaration of Helsinki.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository;

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Giannis A Moustafa http://orcid.org/0000-0002-8216-7108

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34.
2. Fitzpatrick PJ, Macko S. Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys 1984;10:333–40.
3. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252–60.
4. Sjø LD. Ophthalmic lymphoma: epidemiology and pathogenesis. Acta Ophthalmol 2009;87:1–20.
5. Kirkegaard MM, Rasmussen PK, Coupland SE, et al. Conjunctival lymphoma—an international multicenter retrospective study. JAMA Ophthalmol 2016;134:406–14.
6. Svendsen FH, Rasmussen PK, Coupland SE, et al. Lymphoma of the eyelid—an international multicenter retrospective study. Am J Ophthalmol 2017;177:58–68.
7. Olsen TG, Holm F, Mikkelsen LH, et al. Orbital Lymphoma—an international multicenter retrospective study. Am J Ophthalmol 2019;164:1008–14.
8. Clarke GA, Glaser SL. Changing incidence of non-Hodgkin lymphomas in the United States. Cancer 2002;94:2015–23.
9. Rodriguez Torres Y, Ramirez AM, Vazquez Botet R. Pediatric conjunctival lymphoma associated with oral carbamazepine use. Am J Ophthalmol Case Rep 2016;3:31–3.
10. Höh H, Armbrecht S, Decker T, et al. [MALT Lymphoma of the Conjunctiva in a 13-year-old Child—5-Year Relapse-free Follow-up Following Antibiotic Treatment]. Klin Monbl Augenheilk 2016;233:79–84.
11. Wall PB, Traboulsi EI, Hsi ED, et al. Bilateral conjunctival follicular lymphoma in a child. J Aapos 2015;19:183–5.
12. Incesoy-Özdemir S, Yüksel N, Bozkurt C, et al. A rare type of cancer in children: extranodal marginal zone B-cell (MALT) lymphoma of the ocular adnexa. Turk J Pediatr 2014;56:295–8.
13. Taghpirou Zahir S, Mirmansoori SA, Nazemian M, et al. Primary follicular lymphoma of the conjunctiva in a 12-year-old male. Iran J Ped Hematol Oncol 2013;3:83–5.
14. Perry LJF, Jakobiec FA, Rubin PA. Conjunctival pediatric follicular lymphoma. Arch Ophthalmol 2012;130:941–3.
15. Waisbourd M, Leibovich I, Sayar D, et al. Conjunctival lymphoma in a child. Cornea 2011;30:598–9.
16. Frenkel S, Gaitonde SS, Azar N, et al. Conjunctival marginal zone B-cell lymphoma in a 13-year-old child. J Pediatr Ophthalmol Strabismus 2011;48 Online:e1–4.
17. Kram DE, Brathwaite CA, Khabib ZA. Bilateral conjunctival extranodal marginal zone B-cell lymphoma. Pediatr Blood Cancer 2010;55:1414–6.
18. Gaffar M, Thebpatiphat N, Przygodzki R, et al. Primary follicular lymphoma of the conjunctiva in a 6-year-old child. J Aapos 2010;14:538–40.
19. Bakhshi S, Sidhu T. Pediatric orbital and ocular lymphomas. Pediatr Blood Cancer 2008;50:940–1.
20. Fuentes-Pérez G, Saornil MA, Herreras JM, et al. Charge association, hyper-immunoglobulin M syndrome, and conjunctival malf lymphoma. Cornea 2007;26:864–7.
21. Faridipooya K, Mulder MMS, Merks JHM, et al. Precursor B lymphoblastic lymphoma of the orbit in a child: an unusual presentation of a non-Hodgkin lymphoma. Orbit 2006;25:153–7.
22. Tiemmann M, Häring S, Heidemann M, et al. Mucosa-Associated lymphoid tissue lymphoma in the conjunctiva of a child. Virchows Arch 2004;444:198–201.
23. Lucas RS et. Interferon treatment of childhood conjunctival lymphoma. Br J Ophthalmol 2003;87:1191.
24. Liang X, Stork LC, Albano EA. Primary ocular adnexal lymphoma in pediatric patients: report of two cases and review of the literature. Pediatr Dev Pathol 2003;6:458–63.
25. Alford MA, Nerad JA, Conlan RM, et al. Precursor B-cell lymphoblastic lymphoma presenting as an orbital mass. Orbit 1999;18:17–24.
26. Surveilance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 18 Regs Custom Data (with additional treatment fields), Nov 2017 Sub (1973-2015 varying) - Linked To County Attributes - Total U.S., 1969-2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission. Available: www.seer.cancer.gov
27. Percy C. International classification of diseases for oncology (ICD-O). 3rd Edition. Geneva, Switzerland: World Health Organization, 2000.
28. Ruhl JL, CC, Hurlbut A, Ries LAG, et al. Summary stage 2016: codes and coding instructions. Bethesda, MD: National Cancer Institute, 2018.
29. Collaborative Staging Task Force of the American Joint Committee on Cancer. Collaborative staging manual and coding instructions, version 01.03.00, 2006.
30. Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–4.
31. Stacy RC, Jakobiec FA, Schoenfield L, et al. Unifocal and multifocal reactive hyperplasia vs follicular lymphoma of the ocular adnexa. Am J Ophthalmol 2010;150:412–26.
32. Ferry JA, Fung CY, Zukerberg L, et al. Lymphoma of the ocular adnexa: a study of 353 cases. Am J Surg Pathol 2007;31:170–84.
33. Fung CY, Tarbell NJ, Lucarelli MJ, et al. Ocular adnexal lymphoma: clinical behavior of distinct World Health Organization classification subtypes. Int J Radiat Oncol Biol Phys 2003;57:1382–91.
34. Jenkins C et. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol 2000;84:907–13.
35. Coupland SE, Krause L, Delecute HJ, et al. Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Ophthalmology 1998;105:1430–41.
36. Coupland SE, Foss HD, Assaf C, et al. T-Cell and T/natural killer-cell lymphomas involving ocular and ocular adnexal tissues: a clinicopathologic, immunohistochemical, and molecular study of seven cases. Ophthalmology 1999;106:2109–20.
37 Hindsø TG, Esmaeli B, Holm F, et al. International multicentre retrospective cohort study of ocular adnexal marginal zone B-cell lymphoma. *Br J Ophthalmol* 2020;104:357–62.

38 Shields CL, Shields JA. Conjunctival tumors in children. *Curr Opin Ophthalmol* 2007;18:351–60.

39 Yen MT, Bilyk JR, Wladis EJ, et al. Treatments for ocular adnexal lymphoma: a report by the American Academy of ophthalmology. *Ophthalmology* 2018;125:127–36.

40 Decaudin D, de Cremoux P, Vincent-Salomon A, et al. Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. *Blood* 2006;108:1451–60.

41 Moslehi R, Devesa SS, Schairer C, et al. Rapidly increasing incidence of ocular non-Hodgkin lymphoma. *J Natl Cancer Inst* 2006;98:936–9.

42 Schick U, Lerman O, Unsold R, et al. Treatment of primary orbital lymphomas. *Eur J Haematol* 2004;72:186–92.

43 Kirkegaard MM, Coupland SE, Prause JU, et al. Malignant lymphoma of the conjunctiva. *Surv Ophthalmol* 2015;60:444–58.

44 Attarbaschi A, Beishuizen A, Mann G, et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a “watch and wait” strategy after complete resection. *Ann Hematol* 2013;92:1537–41.

45 Tanimoto K, Kaneko A, Suzuki S, et al. Long-Term follow-up results of NO initial therapy for ocular adnexal malt lymphoma. *Ann Oncol* 2006;17:135–40.

46 Shields CL, Shields JA, Carvalho C, et al. Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma. *Ophthalmology* 2001;108:979–84.

47 Munch-Petersen HD, Rasmussen PK, Coupland SE, et al. Ocular adnexal diffuse large B-cell lymphoma: a multicenter International study. *JAMA Ophthalmol* 2015;133:165–73.

48 Rasmussen PK, Coupland SE, Finger PT, et al. Ocular adnexal follicular lymphoma: a multicenter International study. *JAMA Ophthalmol* 2014;132:851–8.

49 Coupland SE, White VA, Rootman J, et al. A TNM-based clinical staging system of ocular adnexal lymphomas. *Arch Pathol Lab Med* 2006;130:1562–7.

50 Aronow ME, Portell CA, Rybicki LA, et al. Ocular adnexal lymphoma: assessment of a tumor-node-metastasis staging system. *Ophthalmology* 2013;120:1915–9.

51 Rath S, Connors JM, Dolman PJ, et al. Comparison of American joint Committee on cancer TNM-based staging system (7th edition) and Ann Arbor classification for predicting outcome in ocular adnexal lymphoma. *Orbit* 2014;33:23–8.